NDLI: Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system

Content Provider	PubMed Central
Author	Salmen, A. Gold, R. Chan, A.
Copyright Year	2013
Abstract	The therapeutic armamentarium for autoimmune diseases of the central nervous system, specifically multiple sclerosis and neuromyelitis optica, is steadily increasing, with a large spectrum of immunomodulatory and immunosuppressive agents targeting different mechanisms of the immune system. However, increasingly efficacious treatment options also entail higher potential for severe adverse drug reactions. Especially in cases failing first-line treatment, thorough evaluation of the risk–benefit profile of treatment alternatives is necessary. This argues for the need of algorithms to identify patients more likely to benefit from a specific treatment. Moreover, paradigms to stratify the risk for severe adverse drug reactions need to be established. In addition to clinical/paraclinical measures, biomarkers may aid in individualized risk–benefit assessment. A recent example is the routine testing for anti-John Cunningham virus antibodies in natalizumab-treated multiple sclerosis patients to assess the risk for the development of progressive multi-focal leucoencephalopathy. Refined algorithms for individualized risk assessment may also facilitate early initiation of induction treatment schemes in patient groups with high disease activity rather than classical escalation concepts. In this review, we will discuss approaches for individiualized risk–benefit assessment both for newly introduced agents as well as medications with established side-effect profiles. In addition to clinical parameters, we will also focus on biomarkers that may assist in patient selection.
Related Links	http://dx.doi.org/10.1111/cei.12258
Ending Page	148
Page Count	14
Starting Page	135
File Format	PDF
ISSN	00099104
e-ISSN	13652249
Journal	Clinical and Experimental Immunology
Issue Number	2
Volume Number	176
Language	English
Publisher	BlackWell Publishing Ltd
Publisher Date	2014-05-01
Access Restriction	Open
Rights Holder	BlackWell Publishing Ltd
Subject Keyword	Immunology Immunology and Allergy Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

RIP2 signaling in Central Nervous System-Infiltrating Dendritic Cells Promotes Cellular Activation, Inflammation and Autoimmune Disease Progression

Type I interferon in neurological disease-the devil from within.

Seminal vesicle fluid ameliorates autoimmune response within central nervous system

B cell targeted therapies in inflammatory autoimmune disease of the central nervous system

The Th17–ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease

Arginase and autoimmune inflammation in the central nervous system

Autoimmune T cell responses in the central nervous system

Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis1

Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system

Similar Documents

Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

RIP2 signaling in Central Nervous System-Infiltrating Dendritic Cells Promotes Cellular Activation, Inflammation and Autoimmune Disease Progression

Type I interferon in neurological disease-the devil from within.

Seminal vesicle fluid ameliorates autoimmune response within central nervous system

B cell targeted therapies in inflammatory autoimmune disease of the central nervous system

The Th17–ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease

Arginase and autoimmune inflammation in the central nervous system

Autoimmune T cell responses in the central nervous system

Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis1

Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system